Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. (PAVM) reports on events occurring on March 1, 2021, and a special meeting of stockholders held on March 4, 2021. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin data. However, it discloses the following financial actions:
- Debt Repayment: The Company repaid its Senior Convertible Note (issued April 2020) and Senior Secured Convertible Note (issued August 2020) in full on March 2, 2021.
- Liquidity Impact: The repayment of debt was executed prior to the issuance of shares that had been approved by stockholders for Nasdaq Listing Rule 5635 compliance.
Material Changes
Significant corporate actions and changes include:
- Stockholder Approvals: Stockholders approved the issuance of shares related to convertible notes (though no shares were ultimately issued due to debt repayment), an amendment to the 2014 Long-Term Incentive Equity Plan, and an amendment to the Employee Stock Purchase Plan (ESPP).
- Equity Plan Increases:
- 2014 Plan: Increased available shares by 2,000,000 (from 7,951,081 to 9,951,081).
- ESPP: Increased authorized shares by 500,000 (from 250,000 to 750,000).
- Executive Compensation: Effective March 1, 2021, base salaries were increased for CEO Lishan Aklog, M.D. (to $613,000/year) and CFO Dennis M. McGrath (to $438,000/year).
- Restricted Stock Awards: The board of Lucid Diagnostics, Inc. (a subsidiary) granted 400,000 shares of restricted stock each to Dr. Aklog and Mr. McGrath, vesting on the second anniversary.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or specific risk factors beyond the context of the stockholder vote. The primary contingency addressed was the resubmission of proposals previously voted on in July 2020 to resolve uncertainty regarding broker non-votes. All proposals were successfully approved.
Investor Verification Checklist
- Confirm the full repayment of the Senior Convertible Notes on March 2, 2021, and verify the cash outflow impact on the balance sheet.
- Review the definitive proxy statement (Schedule 14A filed Jan 27, 2021) for detailed terms of the equity plan amendments.
- Verify the vesting schedules and valuation of the restricted stock awards granted to the CEO and CFO in the subsidiary, Lucid Diagnostics, Inc.
- Check subsequent filings for any dilution resulting from the approved but unissued shares under the convertible notes.